New Delhi, March 26 The capital markets regulator, Sebi, has confirmed its directions against Par Drugs and Chemicals in connection with the proposed slump sale of its core business to a promoter-related entity, pending completion of the investigation.The regulator stated that the observations...
business transfer
financial transactions
india
investigation
par drugs and chemicalsltd
pdcl
phal-jigfinechemicalspvtltd
pjfcpl
regulatory compliance
sebi
securities and exchange board of india
shareholder communication
slump sale
vadodara
valuation